

PATENT
09/646399

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Aventis Pharmaceuticals Products, Inc.

430 Rec'd PCT/PTO **15 SEP 2000**

Art Unit:

Serial No.: **Not yet assigned**

Filed: **Concurrently Herewith**

Title: **Vectors For Transferring Nucleic Acids,
Compositions Containing Them And
Their Uses**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, Washington, D.C. 20231, on

15 Sept. 2000
Date of Deposit

Delra L. Wetherill
Signature

FL6 20187884US
Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,

Karen I. Krupen

Karen I. Krupen, Reg. #34,647
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626

Docket No. ST98008A